Expected impact of applying new 2013 AHA/ACC cholesterol guidelines criteria on the recommended lipid target achievement after acute coronary syndromes

Atherosclerosis

Volumn 239, Issue 1, 2015, Pages 118-124

  Gencer, Baris ^a   Auer, Reto ^b   Nanchen, David ^b   Räber, Lorenz ^c   Klingenberg, Roland ^d   Carballo, David ^a   Blum, Manuel ^e   Vogt, Pierre ^f   Carballo, Sebastian ^a   Meyer, Philippe ^a   Matter, Christian M ^d   Windecker, Stephan ^c   Lüscher, Thomas F ^d   Mach, François ^a   Rodondi, Nicolas ^e  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e UNIVERSITY OF BERN   (Switzerland)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Acute coronary syndromes; Guidelines adherence; Lipids; Secondary prevention

Indexed keywords

ATORVASTATIN; CHOLESTEROL; FLUINDOSTATIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE CORONARY SYNDROME; ADULT; AGE DISTRIBUTION; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; FEMALE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; UNIVERSITY HOSPITAL; AGED; BLOOD; CARDIOLOGY; MULTICENTER STUDY; STANDARDS; SWITZERLAND;

ACUTE CORONARY SYNDROME; AGED; CARDIOLOGY; CHOLESTEROL; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; SWITZERLAND;

EID: 84920894208     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.12.049     Document Type: Article

References (28)

1. O'Gara P.T., Kushner F.G., Ascheim D.D., Casey D.E., Chung M.K., de Lemos J.A., Ettinger S.M., Fang J.C., Fesmire F.M., Franklin B.A., Granger C.B., Krumholz H.M., Linderbaum J.A., Morrow D.A., Newby L.K., Ornato J.P., Ou N., Radford M.J., Tamis-Holland J.E., Tommaso C.L., Tracy C.M., Woo Y.J., Zhao D.X., Anderson J.L., Jacobs A.K., Halperin J.L., Albert N.M., Brindis R.G., Creager M.A., DeMets D., Guyton R.A., Hochman J.S., Kovacs R.J., Ohman E.M., Stevenson W.G., Yancy C.W. 2013 accf/aha guideline for the management of st-elevation myocardial infarction: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation 2013, 127:e362-425.
2. Steg P.G., James S.K., Atar D., Badano L.P., Blomstrom-Lundqvist C., Borger M.A., Di Mario C., Dickstein K., Ducrocq G., Fernandez-Aviles F., Gershlick A.H., Giannuzzi P., Halvorsen S., Huber K., Juni P., Kastrati A., Knuuti J., Lenzen M.J., Mahaffey K.W., Valgimigli M., van 't Hof A., Widimsky P., Zahger D. Esc guidelines for the management of acute myocardial infarction in patients presenting with st-segment elevation. Eur. Heart J. 2012, 33:2569-2619.
3. Hamm C.W., Bassand J.P., Agewall S., Bax J., Boersma E., Bueno H., Caso P., Dudek D., Gielen S., Huber K., Ohman M., Petrie M.C., Sonntag F., Uva M.S., Storey R.F., Wijns W., Zahger D., Bax J.J., Auricchio A., Baumgartner H., Ceconi C., Dean V., Deaton C., Fagard R., Funck-Brentano C., Hasdai D., Hoes A., Knuuti J., Kolh P., McDonagh T., Moulin C., Poldermans D., Popescu B.A., Reiner Z., Sechtem U., Sirnes P.A., Torbicki A., Vahanian A., Windecker S., Achenbach S., Badimon L., Bertrand M., Botker H.E., Collet J.P., Crea F., Danchin N., Falk E., Goudevenos J., Gulba D., Hambrecht R., Herrmann J., Kastrati A., Kjeldsen K., Kristensen S.D., Lancellotti P., Mehilli J., Merkely B., Montalescot G., Neumann F.J., Neyses L., Perk J., Roffi M., Romeo F., Ruda M., Swahn E., Valgimigli M., Vrints C.J., Widimsky P. Esc guidelines for the management of acute coronary syndromes in patients presenting without persistent st-segment elevation: the task force for the management of acute coronary syndromes (acs) in patients presenting without persistent st-segment elevation of the european society of cardiology (esc). Eur. Heart J. 2011, 32:2999-3054.
4. Smith S.C., Benjamin E.J., Bonow R.O., Braun L.T., Creager M.A., Franklin B.A., Gibbons R.J., Grundy S.M., Hiratzka L.F., Jones D.W., Lloyd-Jones D.M., Minissian M., Mosca L., Peterson E.D., Sacco R.L., Spertus J., Stein J.H., Taubert K.A. Aha/accf secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American heart association and American college of cardiology foundation. Circulation 2011, 124:2458-2473.
5. Perk J., De Backer G., Gohlke H., Graham I., Reiner Z., Verschuren M., Albus C., Benlian P., Boysen G., Cifkova R., Deaton C., Ebrahim S., Fisher M., Germano G., Hobbs R., Hoes A., Karadeniz S., Mezzani A., Prescott E., Ryden L., Scherer M., Syvanne M., Scholte op Reimer W.J., Vrints C., Wood D., Zamorano J.L., Zannad F. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur. Heart J. 2012, 33:1635-1701.
6. Third report of the national cholesterol education program (ncep) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel iii) final report. Circulation 2002, 106. 3143-3421.
7. Grundy S.M., Cleeman J.I., Merz C.N., Brewer H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith S.C., Stone N.J. Implications of recent clinical trials for the national cholesterol education program adult treatment panel iii guidelines. Arterioscler. Thromb. Vasc. Biol. 2004, 24:e149-161.
8. Karlson B.W., Barter P.J., Palmer M.K., Lundman P., Nicholls S.J. Comparison of the effects of different statins and doses on lipid levels in patients with diabetes: results from voyager. Nutr. Metabolism, Cardiovasc. Dis.: NMCD 2012, 22:697-703.
9. Martin S.S., Gosch K., Kulkarni K.R., Spertus J.A., Mathews R., Ho P.M., Maddox T.M., Newby L.K., Alexander K.P., Wang T.Y. Modifiable factors associated with failure to attain low-density lipoprotein cholesterol goal at 6 months after acute myocardial infarction. Am. Heart J. 2013, 165:26-33. e23.
10. Melloni C., Shah B.R., Ou F.S., Roe M.T., Smith S.C., Pollack C.V., Ohman M., Gibler W.B., Peterson E.D., Alexander K.P. Lipid-lowering intensification and low-density lipoprotein cholesterol achievement from hospital admission to 1-year follow-up after an acute coronary syndrome event: results from the medications applied and sustained over time (maintain) registry. Am. Heart J. 2010, 160:1121-1129. 1129 e1121.
11. Arnold S.V., Kosiborod M., Tang F., Zhao Z., Maddox T.M., McCollam P.L., Birt J., Spertus J.A. Patterns of statin initiation, intensification, and maximization among patients hospitalized with an acute myocardial infarction. Circulation 2014, 129(12):1303-1309.
12. Stone N.J., Robinson J., Lichtenstein A.H., Merz C.N., Blum C.B., Eckel R.H., Goldberg A.C., Gordon D., Levy D., Lloyd-Jones D.M., McBride P., Schwartz J.S., Shero S.T., Smith S.C., Watson K., Wilson P.W. 2013 acc/aha guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/American heart association task force on practice guidelines. Circulation 2013, 129(25 Suppl. 2):S49-S73.
13. Rodondi N., Peng T., Karter A.J., Bauer D.C., Vittinghoff E., Tang S., Pettitt D., Kerr E.A., Selby J.V. Therapy modifications in response to poorly controlled hypertension, dyslipidemia, and diabetes mellitus. Ann. Intern Med. 2006, 144:475-484.
14. Arnold S.V., Spertus J.A., Masoudi F.A., Daugherty S.L., Maddox T.M., Li Y., Dodson J.A., Chan P.S. Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after acute myocardial infarction. J.Am. Coll. Cardiol. 2013, 62:1791-1801.
15. Auer R., Gencer B., Raber L., Klingenberg R., Carballo S., Carballo D., Nanchen D., Cornuz J., Vader J.P., Vogt P., Juni P., Matter C.M., Windecker S., Luscher T.F., Mach F., Rodondi N. Quality of care after acute coronary syndromes in a prospective cohort with reasons for non-prescription of recommended medications. PloS One 2014, 9:e93147.
16. Thygesen K., Alpert J.S., Jaffe A.S., Simoons M.L., Chaitman B.R., White H.D., Katus H.A., Lindahl B., Morrow D.A., Clemmensen P.M., Johanson P., Hod H., Underwood R., Bax J.J., Bonow R.O., Pinto F., Gibbons R.J., Fox K.A., Atar D., Newby L.K., Galvani M., Hamm C.W., Uretsky B.F., Steg P.G., Wijns W., Bassand J.P., Menasche P., Ravkilde J., Ohman E.M., Antman E.M., Wallentin L.C., Armstrong P.W., Januzzi J.L., Nieminen M.S., Gheorghiade M., Filippatos G., Luepker R.V., Fortmann S.P., Rosamond W.D., Levy D., Wood D., Smith S.C., Hu D., Lopez-Sendon J.L., Robertson R.M., Weaver D., Tendera M., Bove A.A., Parkhomenko A.N., Vasilieva E.J., Mendis S. Third universal definition of myocardial infarction. Circulation 2012, 126:2020-2035.
17. Cannon C.P., Brindis R.G., Chaitman B.R., Cohen D.J., Cross J.T., Drozda J.P., Fesmire F.M., Fintel D.J., Fonarow G.C., Fox K.A., Gray D.T., Harrington R.A., Hicks K.A., Hollander J.E., Krumholz H., Labarthe D.R., Long J.B., Mascette A.M., Meyer C., Peterson E.D., Radford M.J., Roe M.T., Richmann J.B., Selker H.P., Shahian D.M., Shaw R.E., Sprenger S., Swor R., Underberg J.A., Van de Werf F., Weiner B.H., Weintraub W.S. 2013 accf/aha key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the american college of cardiology foundation/American heart association task force on clinical data standards (writing committee to develop acute coronary syndromes and coronary artery disease clinical data standards). Circulation 2013, 127:1052-1089.
18. Fyfe T., Baxter R.H., Cochran K.M., Booth E.M. Plasma-lipid changes after myocardial infarction. Lancet 1971, 2:997-1001.
19. Ryder R.E., Hayes T.M., Mulligan I.P., Kingswood J.C., Williams S., Owens D.R. How soon after myocardial infarction should plasma lipid values be assessed?. Br. Med. J. Clin. Res. Ed. 1984, 289:1651-1653.
20. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972, 18:499-502.
21. Hayward R.A., Krumholz H.M. Three reasons to abandon low-density lipoprotein targets: an open letter to the adult treatment panel iv of the national institutes of health. Circulation Cardiovasc. Qual. Outcomes 2012, 5:2-5.
22. Gehi A.K., Ali S., Na B., Whooley M.A. Self-reported medication adherence and cardiovascular events in patients with stable coronary heart disease: the heart and soul study. Arch. Intern Med. 2007, 167:1798-1803.
23. Robins J.M., Finkelstein D.M. Correcting for noncompliance and dependent censoring in an aids clinical trial with inverse probability of censoring weighted (ipcw) log-rank tests. Biometrics 2000, 56:779-788.
24. Jadad A.R., To M.J., Emara M., Jones J. Consideration of multiple chronic diseases in randomized controlled trials. JAMA: J. Am. Med. Assoc. 2011, 306:2670-2672.
25. Ho P.M., Magid D.J., Shetterly S.M., Olson K.L., Maddox T.M., Peterson P.N., Masoudi F.A., Rumsfeld J.S. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am. Heart J. 2008, 155:772-779.
26. Ho P.M., Bryson C.L., Rumsfeld J.S. Medication adherence: its importance in cardiovascular outcomes. Circulation 2009, 119:3028-3035.
27. Naderi S.H., Bestwick J.P., Wald D.S. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am. J. Med. 2012, 125:882-887. e881.
28. Lemstra M., Blackburn D., Crawley A., Fung R. Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis. Can. J. Cardiol. 2012, 28:574-580.